Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are investigating how a high-protein, high-fiber meal eaten before fasting affects feelings of fullness and blood sugar levels during fasting hours in healthy adults. This randomized crossover study compares a standardized high-protein, high-fiber pre-fast meal to a low-protein, low-fiber meal guided by dietary instructions, aiming to understand their impact on appetite and glycemic responses. Participants will complete two study periods, each lasting two consecutive days, with a three-day break in between. In one period, they will consume a provided high-protein, high-fiber meal including oats, Greek yogurt, peanut butter, dried cranberries, and almonds. In the other period, they will follow written instructions to consume a low-protein, low-fiber pre-fast meal without calorie limits. Throughout the study, participants feelings of hunger, fullness, desire to eat, and anticipated food intake will be measured at specific times during fasting. Blood sugar levels will be continuously monitored using a glucose monitor. Researchers will analyze the relationship between glucose changes and appetite sensations. The study includes fasting, meal consumption, monitoring, and washout phases to thoroughly evaluate effects.
Actively Recruiting
Researchers are conducting an ongoing international observational program called the Fabry Registry to track routine clinical outcomes in patients diagnosed with Fabry disease. This registry includes all patients regardless of their treatment status and aims to improve understanding of the diseases variability, progression, and natural history, including in female patients. It also supports development of monitoring recommendations, characterization of the Fabry population, and evaluation of the long-term safety and effectiveness of Fabrazyme4. The study features a Fabry Pregnancy Sub-registry, which observes pregnancy outcomes in women enrolled in the main registry. This sub-registry collects data on medical and obstetric history, pregnancy, birth outcomes, and infant growth up to 36 months postpartum. Neither the main registry nor the pregnancy sub-registry involve experimental interventions, and patients receive standard care as determined by their treating physicians. Participants undergo clinical assessments and receive their usual care during the registry. Data collected includes safety and effectiveness of treatments like Fabrazyme4 over long periods, as well as pregnancy complications and infant growth measurements. The study is designed to last until 2034, with ongoing monitoring and data collection to support patient care and research without altering treatment plans.
Actively Recruiting
Researchers are observing patients with Gaucher disease in the International Collaborative Gaucher Group ICGG Gaucher Registry to understand the diseases variability, progression, and natural history. The study aims to help guide treatment decisions and improve patient care by providing data on patient outcomes and the long-term effectiveness of treatments like imiglucerase and eliglustat. There is also a Gaucher Pregnancy Sub-registry focusing on pregnancy outcomes and infant growth in women with Gaucher disease. Participants in the Registry do not receive experimental treatments but continue with their usual clinical assessments and care as determined by their physicians. The Pregnancy Sub-registry collects data from pregnant women with Gaucher disease, including medical and obstetric history, pregnancy, birth details, and infant growth up to 36 months postpartum. Both registries do not involve any experimental interventions and support standard care practices. During the study, participants undergo routine clinical assessments and provide medical data as part of their ongoing care. Data collected includes patient outcomes, monitoring recommendations, and pregnancy-related information when applicable. The studys primary outcomes include generating monitoring guidelines for Gaucher disease and tracking pregnancy and infant growth outcomes. The registry is ongoing and international, with data collected over several decades to enhance understanding and optimize care for Gaucher disease.